Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Suzuoki, M.
Right arrow Articles by Katoh, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Suzuoki, M.
Right arrow Articles by Katoh, H.
Related Collections
Right arrow Prognostic factors
Annals of Surgical Oncology 9:388-393 (2002)
© 2002 Society of Surgical Oncology

ORIGINAL ARTICLES

RCAS1 Expression as a Prognostic Factor After Curative Surgery for Extrahepatic Bile Duct Carcinoma

Masato Suzuoki, MD, Yasuhiro Hida, MD, Masaki Miyamoto, MD, Taro Oshikiri, MD, Kei Hiraoka, MD, Yoshihiro Nakakubo, MD, Toshiya Shinohara, MD, Tomoo Itoh, MD, Shunichi Okushiba, MD, Satoshi Kondo, MD and Hiroyuki Katoh, MD

From the Department of Surgical Oncology (MS, YH, MM, TO, KH, YN, SO, SK, HK), Division of Cancer Medicine, Hokkaido University Graduate School of Medicine, Hokkaido, Japan; Department of Pathology (TS), Teinekeijinkai Hospital, Sapporo, Japan; and Department of Surgical Pathology (TI), Hokkaido University Hospital, Sapporo, Japan.

Correspondence: Address correspondence and reprint requests to: Masato Suzuoki, MD, Department of Surgical Oncology, Division of Cancer Medicine, Hokkaido University Graduate School of Medicine, Kita-15, Nishi-7, Kita-ku, Sapporo, Hokkaido 060-8648, Japan; Fax: 81-11-706-7158; E-mail: suzuoki@ med.hokudai.ac.jp.

Background: RCAS1 (receptor-binding cancer antigen expressed on SiSo cells) is a cancer cell-surface antigen and has been identified as a prognostic factor in several cancers. It is thought that tumor cells escape from immune attack by expressing RCAS1, which induces apoptosis in receptor-positive immune cells. We investigated the relationship between RCAS1 expression and clinicopathologic features and clinical outcome in patients with extrahepatic bile duct carcinoma (EBDC) who underwent curative resection.

Methods: RCAS1 expression was determined by immunohistochemistry in 60 patients with EBDC who underwent curative resection from 1992 to 1999. The patients were divided into two groups on the basis of the extent of RCAS1 expression: a low-expression group (immunoreactivity in <25% of cells) and a high-expression group. Expression was correlated with clinicopathologic features and prognosis.

Results: RCAS1 was expressed in 52 (86.7%) of 60 tumors and at a high frequency in all histopathologic stages. High expression of RCAS1 was detected in 46 (76.7%) of 60 cases. No correlation existed between the pattern of RCAS1 expression and any clinicopathologic feature, although high expression did correlate with poor prognosis. High RCAS1 expression was an independent negative predictor for survival.

Conclusions: RCAS1 expression predicts poor outcome in resectable EBDC.

Key Words: Receptor-binding cancer antigen expressed on SiSo cells (RCAS1) • Extrahepatic bile duct carcinoma • Immunohistochemistry • Prognostic factor




This article has been cited by other articles:


Home page
 J. Clin. Pathol.Home page
K Leelawat, T Watanabe, M Nakajima, S Tujinda, C Suthipintawong, and V Leardkamolkarn
Upregulation of tumour associated antigen RCAS1 is implicated in high stages of colorectal cancer
J. Clin. Pathol., October 1, 2003; 56(10): 764 - 768.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the Society of Surgical Oncology.